Development and regulation of biosimilars: current status and future challenges.
about
Regulatory considerations in oncologic biosimilar drug developmentBiosimilars: the process is the product. The example of recombinant streptokinase.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Regulatory and clinical considerations for biosimilar oncology drugsBioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.Biosimilars advancements: Moving on to the future.An overview of developing TNF-α targeted therapy for the treatment of psoriasis.Biosimilar regulation in the EU.Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.Introduction of biosimilar insulins in Europe.Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury.Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars: Imitation Games.Availability and quality of illegitimate somatropin products obtained from the Internet.Enhanced expression of a biosimilar monoclonal antibody with a novel NS0 platform.Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.A biosimilarity index for psoriasis.A self-deploying drug release device using polymeric films.Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).Laboratory Medicine to improve biological therapeutic treatmentChallenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
P2860
Q27027947-A00A2759-07B0-43D1-8EB8-5D2C64206294Q34559360-FDB060F4-B294-4C60-A1B3-4014CF80D842Q35162053-334B0A24-5811-4065-B516-98067D584BAFQ35505833-DEB35F9D-1E2B-4ECF-B9CB-322AE7E6FBA7Q36215497-293E8509-C891-4D8E-8656-A80C625E7175Q38364577-ED9CEF6F-5162-47F2-BD92-4A7B809DD130Q38569794-9BF515D0-4B89-4DEF-9CFE-18BDBE36A384Q38570723-DBB93298-B973-4A93-A848-C7F4A43946D1Q39260479-823B7FAE-9BD6-456F-B55C-B865CB477ACEQ39368850-772F9B3C-AB21-462B-9B4B-8B8DC67FA29FQ40766694-A10FF6BD-CD37-4A5B-B7D7-3D6EF33E43A2Q40897367-AD8DCE8A-58D3-47AC-B6A6-89CFFE586150Q45869626-A9FA457C-380F-4ED5-8BA1-7822EF7B508CQ47656264-C6534931-0A19-4D94-A078-93F67D4D24BEQ47884525-0F1D2895-4427-4F44-ABA5-D84B6E82897EQ48196852-0C4EF924-04B8-4B6E-8E90-4520BE64A696Q48324789-D19349C2-ACE2-42F0-9990-FD492440F469Q50098437-EF75ED79-597A-408F-921C-9B9B6EC561BBQ50204734-3D4403A2-8A63-40DD-A17B-ADEA1C96F92CQ50933780-FC67E1EA-7320-4144-81C5-C185F69241C8Q55111318-6DCBF509-A586-46AA-8BD8-8073E63650A7Q58055739-8960136B-FE91-4BBC-8D68-638E2E577C01Q59129650-AE37948A-4D9A-430E-8911-92379246393B
P2860
Development and regulation of biosimilars: current status and future challenges.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development and regulation of biosimilars: current status and future challenges.
@en
type
label
Development and regulation of biosimilars: current status and future challenges.
@en
prefLabel
Development and regulation of biosimilars: current status and future challenges.
@en
P2860
P1433
P1476
Development and regulation of biosimilars: current status and future challenges
@en
P2093
Christian K Schneider
P2860
P2888
P304
P356
10.1007/S40259-013-0020-Y
P577
2013-06-01T00:00:00Z